Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Inclusion Criteria: * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Previously untreated classical Hodgkin lymphoma (i.e., nodular sclerosis, mixed cellularity, lymphocyte depleted, lymphocyte-rich, and not otherwise specified \[NOS\]); nodular lymphocyte predominant Hodgkin lymphoma is not eligible * Stage II, III, and IV disease by Ann Arbor classification * Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 * Patients must have bi-dimensional measurable disease documented in the lymphoma baseline tumor assessment form within 30 days prior to registration (at least 1.5 cm); patients with non-measurable disease in addition to measurable disease must have been assessed within 60 days prior to registration * Patients must have a bone marrow biopsy (bilateral preferred, unilateral acceptable) within 60 days prior to registration * Patients must have a multi gated acquisition scan (MUGA) or echocardiogram within 60 days prior to study registration and the ejection fraction must be \>= 45% * Absolute neutrophil count (ANC) \> 1000/mm\^3 * Platelet count \> 75,000/mm\^3 * Creatinine \< 2.5 mg/dl * Bilirubin \< 3.0 mg/dl * Patients with documented marrow involvement by lymphoma at the time of registration are not required to meet the above hematologic paramete…